Merck Stock Plummets 4.12% on Keytruda Setback and Regulatory Hurdles, Trading Volume Ranks 40th

On May 14, 2025, Merck's trading volume reached 17.63 billion, ranking 40th in the day's stock market. Merck (MRK) fell 4.12%, marking two consecutive days of decline, with a total drop of 8.65% over the past two days.

Merck's stock price has been under pressure due to recent developments. The company's key drug, Keytruda, faced a setback as a clinical trial showed mixed results. This news has raised concerns among investors about the drug's future prospects and its impact on Merck's revenue.

Additionally, Merck is facing regulatory challenges in Europe. The European Medicines Agency (EMA) has delayed the approval of one of Merck's new drugs, citing the need for more data. This delay has added to the uncertainty surrounding Merck's pipeline and has contributed to the recent sell-off in the stock.

Despite these challenges, Merck remains optimistic about its long-term prospects. The company has a strong pipeline of drugs in development and continues to invest in research and development. Merck's management has reiterated its commitment to delivering value to shareholders and has assured investors that the company is well-positioned to navigate the current challenges.